Mutant IDH1-IN-2 is primarily used in research and development for targeting cancers associated with mutations in the IDH1 gene. It acts as an inhibitor, specifically designed to block the abnormal activity of mutant IDH1 enzymes, which are often linked to certain types of gliomas and acute myeloid leukemia (AML). By inhibiting this enzyme, it helps to reduce the production of the oncometabolite 2-hydroxyglutarate (2-HG), which is known to promote tumor growth and progression. This makes it a promising candidate for therapeutic applications in precision medicine, particularly for patients with IDH1-mutated cancers. Additionally, it is utilized in preclinical studies to better understand the molecular mechanisms of IDH1 mutations and to evaluate the efficacy of targeted therapies.